文献速递预防保健、筛查与疫苗老年与多病共存

mRNA-1273疫苗对德尔塔、缪等变异株的有效性:检测阴性病例对照研究

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
PubMed 文献 · BMJ · 2021-12-15

该检测阴性病例对照研究纳入2021年3月至7月Kaiser Permanente Southern California的8153例SARS-CoV-2检测者,评估mRNA-1273疫苗对变异株感染及住院的有效性。两剂疫苗对德尔塔感染有效性86.7%,对德尔塔住院97.5%,但对德尔塔感染的有效性随时间下降,≥65岁人群较低。

要点

  • 两剂mRNA-1273对德尔塔感染有效性86.7%,对德尔塔住院97.5%。
  • 对德尔塔感染的有效性从接种后14-60天的94.1%降至151-180天的80.0%。
  • ≥65岁人群对德尔塔感染的有效性(75.2%)低于18-64岁人群(87.9%)。

核心结论

  • 两剂mRNA-1273对所有SARS-CoV-2变异株高度有效,尤其对COVID-19住院。
  • 对德尔塔感染的有效性随接种时间推移中度下降。

研究设计与样本

  • 检测阴性病例对照研究,纳入2021年3月1日至7月27日Kaiser Permanente Southern California成年成员,共8153例病例及其匹配对照。

主要发现

  • 两剂疫苗对德尔塔感染有效性86.7%(95%CI 84.3%至88.7%),对阿尔法98.4%(96.9%至99.1%),对缪90.4%(73.9%至96.5%)。
  • 对德尔塔住院有效性97.5%(92.7%至99.2%)。
  • 对德尔塔感染有效性从接种后14-60天的94.1%(90.5%至96.3%)降至151-180天的80.0%(70.2%至86.6%)。
  • ≥65岁人群对德尔塔感染有效性75.2%(59.6%至84.8%),18-64岁人群87.9%(85.5%至89.9%)。
  • 单剂疫苗对德尔塔感染有效性77.0%(60.7%至86.5%)。

关键数值与推荐

  • 两剂mRNA-1273对德尔塔感染有效性86.7%(95%CI 84.3%至88.7%)。
  • 两剂mRNA-1273对德尔塔住院有效性97.5%(95%CI 92.7%至99.2%)。
  • 对德尔塔感染有效性在接种后151-180天为80.0%(95%CI 70.2%至86.6%)。
  • ≥65岁人群对德尔塔感染有效性75.2%(95%CI 59.6%至84.8%)。

临床怎么用

  • mRNA-1273两剂接种对德尔塔等变异株感染和住院均有高度保护。
  • 随时间推移对德尔塔感染的保护下降,老年人群保护较低,需关注加强免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. DESIGN: Test negative case-control study. SETTING: Kaiser Permanente Southern California (KPSC), an integrated healthcare system. PARTICIPANTS: Adult KPSC members with a SARS-CoV-2 positive test sent for whole genome sequencing or a negative test from 1 March 2021 to 27 July 2021. INTERVENTIONS: Two dose or one dose vaccination with mRNA-1273 (Moderna covid-19 vaccine) ≥14 days before specimen collection versus no covid-19 vaccination. MAIN OUTCOME MEASURES: Outcomes included infection with SARS-CoV-2 and hospital admission with covid-19. In pre-specified analyses for each variant type, test positive cases were matched 1:5 to test negative controls on age, sex, race/ethnicity, and specimen collection date. Conditional logistic regression was used to compare odds of vaccination among cases versus controls, with adjustment for confounders. Vaccine effectiveness was calculated as (1-odds ratio)×100%. RESULTS: The study included 8153 cases and their matched controls. Two dose vaccine effectiveness was 86.7% (95% confidence interval 84.3% to 88.7%) against infection with the delta variant, 98.4% (96.9% to 99.1%) against alpha, 90.4% (73.9% to 96.5%) against mu, 96-98% against other identified variants, and 79.9% (76.9% to 82.5%) against unidentified variants (that is, specimens that failed sequencing). Vaccine effectiveness against hospital admission with the delta variant was 97.5% (92.7% to 99.2%). Vaccine effectiveness against infection with the delta variant declined from 94.1% (90.5% to 96.3%) 14-60 days after vaccination to 80.0% (70.2% to 86.6%) 151-180 days after vaccination. Waning was less pronounced for non-delta variants. Vaccine effectiveness against delta infection was lower among people aged ≥65 years (75.2%, 59.6% to 84.8%) than those aged 18-64 years (87.9%, 85.5% to 89.9%). One dose vaccine effectiveness was 77.0% (60.7% to 86.5%) against infection with delta. CONCLUSIONS: Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19. However, vaccine effectiveness against infection with the delta variant moderately declined with increasing time since vaccination.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021. PMID: 34911691. doi:10.1136/bmj-2021-068848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。